Quick Answer
Evommune, Inc. reported Diluted EPS of $11.22 per share (loss) for fiscal year 2025.
Evommune, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$11.22 | +75.2% |
| 2024 | -$45.29 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$8.07 | +22.9% | +22.9% |
| September 30, 2024 | -$10.47 | — | — |
- Evommune, Inc. showed an increase of +75.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Evommune, Inc.’s diluted eps has grown by 75.2% (from $45.29 per share (loss) to $11.22 per share (loss)).
- The most recent figure is from Evommune, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: